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Zusammenfassung 
 
Fibroblasten spielen eine zentrale Rolle in der Pathogenese von Fibrose, da sie die 
Hauptquelle der extrazellulären Matrixproteine sind. Allerdings ist die Regulation der 
Fibroblasten bei der Bildung der  extrazellulären Matrix, der Mechanismus der zum 
Kontrollverlusst der extrazellulären Matrix Homeostase bei der chronischen Entzündung 
führt, und die Funktion, die humane Darmmastzellen dabei spielen, noch nicht verstanden. 
Mastzellen besitzen eine Schlüsselrolle bei allergischen Reaktionen, sind aber auch an 
der Immunabwehr, bei Gewebeneubildungsprozessen wie z.B. der Wundheilung, der 
Angiogenese und der Fibrogenese beteiligt. Die Arbeitgruppe von Prof. Bischoff konnte 
bereits zeigen, dass humane Darmfibroblasten Apoptose in humanen Darmmastzellen 
unabhängig von den bekannten Mastzell-Wachstumsfaktoren Stem Cell Factor, IL-3, IL-4 
und Nerve Growth Factor unterdrücken. In meiner Arbeit konnte ich nun zeigen, dass die 
Effekte von Fibroblasten auf Mastzellen von IL-6 vermittelt werden. Es wurden die 
molekularen Interaktionen zwischen humanen Mastzellen und humanen Fibroblasten, beide 
isoliert und aufgereinigt aus Darmgewebe, untersucht. Das Überleben der Mastzellen bei 
Anwesenheit von Fibroblasten konnte mit einem anti-IL-6 Antikörper verhindert werden. 
Mastzellen, die mit IL-6 inkubiert wurden, überlebten bis zu 3 Wochen, genauso wie 
Mastzellen, die mit Fibroblasten co-kultiviert wurden. Stimuliert durch die Co-Kultivierung 
mit Mastzellen oder durch Mastzellmediatoren, produzieren Darmfibroblasten IL-6. 
Außerdem bilden Fibroblasten nach Stimulation mit Mastzellmediatoren das antifibrotische 
Enzym Matrixmetalloproteinase-1. Matrixmetalloproteinase-1 wird als multifunktionelles 
Molekül betrachtet, da es nicht nur am Umsatz der Collagenfasern in der extrazellulären 
Matrix beteiligt ist, sondern auch an der Teilung zahlreicher “Nicht-Matrix“-Substrate und 
Zelloberflächenmoleküle, weshalb ihm eine Rolle bei der Regulation der Zellfunktionen 
zugeschrieben wird. Erstaunlicherweise verlieren Fibroblasten, die mit Mastzellen co-
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kultiviert, oder mit Matrixmetalloproteinase-1 behandelt werden, ihre Konfluenz. Die von 
Mastzellen in Fibroblasten ausgelöste Matrixmetalloproteinase-1 Expression, hängt von dem 
MEK/ERK Signalweg ab, wie unsere Inhibitionsexperimente zeigten. 
 Zusammenfassend kann gesagt werden, dass die vorliegende in vitro Studie zeigt, dass 
Mastzellmediatoren Fibroblasten stimulieren IL-6 zu bilden und umgekehrt die Bildung von 
IL-6 durch Fibroblasten das Überleben der Mastzellen fördert. Außerdem induzieren 
Mastzellmediatoren die Expression von Matrixmetalloproteinase-1 in Fibroblasten. Die 
Ergebnisse meiner Arbeit deuten darauf hin, dass Mastzellen, die an fibrotischen Stellen 
akkumulieren, Fibrogenese eher unterdrücken als Fibrogenese unterstützen. 
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Summary 
 
Fibroblasts (FB) play a central role in the pathogenesis of fibrosis since they are the 
major source of extracellular matrix proteins. However, the regulation of extracellular matrix 
production in fibroblasts, the mechanisms that lead to loss of control of extracellular matrix 
homeostasis during chronic inflammation and the role of human intestinal mast cells are still 
not fully understood. 
Mast cells are key effector cells in allergic reactions but also involved in host defense 
and tissue remodeling processes such as wound healing, angiogenesis, and fibrogenesis. The 
group pf Prof. Bischoff has shown previously that human intestinal fibroblasts suppress 
apoptosis in human intestinal MC independent of the known human mast cell growth factors 
stem cell factor interleukin-3, interleukin-4, and nerve growth factor.In this work I could 
show that the effects of fibroblasts on mast cells are mediated by interleukin-6. The molecular 
crosstalk between human mast cells and human fibroblasts, both isolated and purified from 
intestinal tissue was analyzed. Mast cells survival in the presence of fibroblasts could be 
blocked using an anti-interleukin-6 antibody. Mast cells incubated with interleukin-6 survived 
for up to 3 weeks. Intestinal fibroblasts produced interleukin-6 upon direct stimulation by 
mast cells in co-culture or by mast cell mediators such as tumor necrosis factor alpha, 
interleukin-1 beta, tryptase or histamine. Moreover, fibroblasts stimulated by mast cell 
mediators produce the antifibrotic enzyme matrix metalloproteinase-1. Matrix 
metalloproteinase-1 should be considered as multifunctional molecule since it participates not 
only in the turnover of collagen fibrils in the extracellular space but also in the cleavage of a 
number of non-matrix substrates and cell surface molecules suggesting a role in the regulation 
of cellular behaviour. Noteworthy, fibroblasts co-cultured with mast cells or treated with 
matrix metalloproteinase-1 lost confluence. Matrix metalloproteinase-1 expression in 
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fibroblasts triggered by mast cells was dependent on the MEK/ERK cascade as shown by 
inhibitor experiments. 
In conclusion, this study show that mast cells mediators stimulate fibroblasts to produce 
interleukin-6, and, vice versa, fibroblasts derived interleukin-6 supports mast cells survival. 
Furthermore, mast cell mediators induce expression of matrix metalloproteinase-1 in 
fibroblasts, a key enzyme in fibrolysis, which in turn leads to lost of confluence of cultured 
fibroblasts. Taken together the results of my work suggest that mast cells accumulating at 
sites of fibrosis rather limite than promote fibrogenesis. 
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Abbrevations/Abkürzungsverzeichnis 
 
Ab   antibody 
Ag   antigen 
cd   cluster of differentiation 
CD   Crohn´s disease 
cDNA   complementary deoxyribonucleic acid 
DNA   deoxyribonucleic acid 
DNAase  deoxyribonuclease 
dNTP   2´-deoxynucleoside5´-triphosphate 
ECM   extracellular matrix 
ELISA  enzyme-linked immunosorbent assay 
ERK   extracellular signal-regulated kinase 
FB   fibroblasts 
FcR   Fc receptors 
FCS   fetal calf serum 
g   gram (only with numbers) 
GAPDH  glyceraldehydes-3-phosphate dehydrogenase 
G-CSF  granulocyte CSF 
GDP   guanosine diphosphate 
GM-CSF  granulocyte-macrophage CSF 
GTP   guanosine triphosphate 
h   hour (only with numbers) 
IEC   intestinal epithelial cells 
IFN   interferon 
Ig   immunoglobulin 
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IL   interleukin 
HSR   kinase suppressor of Ras 
mAb   monoclonal Ab 
MACS  magnetic-activated cell sorting 
MAPK   mitogen-activated protein kinase 
MC   mast cells 
MCT   tryptase positive and chymase negative mast cells 
MCTC   tryptase and chymase psotive mast cells 
MEK   MAPK kinase 
mg   milligram (only with numbers) 
min   minute (only with numbers) 
ml   milliter (only with numbers) 
mRNA  messenger RNA 
µg   microgram (only with numbers) 
µl   microliter (only with numbers) 
n   number in study 
NS   not significant 
OD   optical density 
OVA   ovalbumin 
p   probability 
P   phosphorylation 
PBS   phosphate-buffered saline 
PCR   polymerase chain reaction 
PI3K   phosphatidylinositol 3-kinase 
PP2A   protein phosphatase 2A 
RKIP   raf kinase inhibitor protein 
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RNA   ribonucleic acid 
RNase  ribonuclease 
rpm   revolutions per minute 
rRNA   ribosomal RNA 
RT-PCR  reverse transcriptase polymerase chain reaction 
s   second (only with numbers) 
SMA   smooth-muscle cell actin 
SMC   smooth-muscle cell 
SRF   serum response factor 
TLR   Toll-like receptor 
TNF   tumor necrosis factor 
U   unit (only with numbers) 
UC   ulcerative colitis 
UV   ultraviolet 
v/v   volume to volume ratio (%) 
W   watt (only with numbers) 
wk   week (only with numbers) 
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Introduction 
1.1 Mast cells 
1.1.1 Characteristics of mast cells  
MC were known as a key cell type involved in type I hypersensitivity (2). Until last two 
decades, this cell type was recognized to be widely involved in a number of non allergic 
diseases in internal medicine including chronic obstructive pulmonary disease, Crohn´s 
disease, fibrosis, liver cirrhosis, and cardiomyopathy (3) (Table 1). 
Table 1: Mast cells and non allergic diseases  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modified from He (3) 
Chronic obstructive pulmory disease  
Cor pulmonale
Bronchectasis
Acute respiratory distress syndrome               
Bronchiolitis obliterans organizing pneumonia               
Cystic fibrosis                                                 
Intestitial lung disease                                                 
Silicosis                                                       
Sarcoidosis
Gastritis                                                       
Ulcerative colitis                                              
Crohn´s disease                                                 
Liver cirrhosis                                                 
Hepatitis                                                       
Pancreatitis
Atherosclerosis                                                 
Myocardial infarction
Congenital heart disease 
Myocarditis
Cardiomyopathy
Diabetes
Thyroiditis
Osteoporosis 
Glomerulonephritis
Nephropathy                                                     
Multiple sclerosis
Disease MC hyperplasia Release MC mediators
Yes                                 Yes
Yes                                 No
Yes                                 Yes
Yes                                 Yes
Yes                                 Yes
Yes                                 Yes
Yes                                 Yes
Yes                                  No
Yes                                 Yes
Yes                                 Yes
Yes                                  Yes
Yes                                 Yes
Yes                                 No 
Yes                                 No
Yes                                 Yes
Yes                                 No
Yes                                 Yes
Yes                                 No
Yes                                 No
Yes                                 Yes
Yes                                 No
Yes                                 No
Yes                                 No
Yes                                 No
Yes                                 No
Yes                                 No
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MC are round or oval cells with an unlobed nucleus that are found in many tissues such 
as the skin and at mucosal sites where they preferentially locate around blood vessels and 
nerves. MC derive from CD34+ hematopoietic progenitor cells. Previous studies (4, 5) 
suggested that bone marrow derived MC progenitors circulate in the peripheral blood and 
subsequently migrate into the tissue where they undergo final maturation under the influence 
of local microenvironmental factors. The regulation of this process and the stage of 
maturation at which MC migrate from the blood into the tissue remain largely unknown. 
Under normal conditions cells expressing typical markers of mature MC are not found in 
peripheral blood. Human MC are commonly classified according to their protease contents. 
MC containing tryptase only (MCT) predominate in the lung and intestinal mucosa. Tryptase 
and chymase positive MC (MCTC) are mainly located in the skin and the intestinal submucosa 
(6, 7).  
Stem cell factor (SCF) has been described as an essential factor for both MC maturation 
and maintenance of mature MC in the body since it induces MC proliferation and suppresses 
MC apoptosis. The importance of SCF and its receptor c-kit is stressed by the fact that SCF- 
or c-kit-deficient mice basically lack MC, even though in vitro IL-3 is also capable of 
inducing partial MC development in rodents, but not in humans. Most studies have shown that 
human MC development from progenitor cells and growth of mature tissue derived MC is 
essentially SCF-dependent (8). 
 
1.1.2 Role of mast cells in physiology  
 
1.1.2.1 Blood flow and coagulation 
MC have been associated with bleeding in a variety of disorders. In cutaneous 
mastocytosis, for example, gastrointestinal and cutaneous bleeding has been attributed to the 
heparin released by MC (9). Skin mast cells have also been shown to prolong the bleeding 
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time and to inhibit thrombin generation (10). The clinical association between mast cells, 
bleeding, and fibronolysis has led some investigators to propose recently that mast cells may 
play a physiologic role in promoting a profibrinolytic and antithrombotic state within injured 
tissues (11). 
One possible mediator of this anticoagulant activity is mast cell tryptase (12). The serine 
protease tryptase is the major protein component of human mast cell secretory granules, 
where it exists in a complex with heparin proteoglycan (13). Both heparin and tryptase are 
found only in mast cell granules and are tightly to one another under physiologic conditions 
(13). Recent evidence indicates that there is a structural requirement for heparin to bridge 
tryptase monomers to form enzymatically active tryptase tetramers (14). 
The physiologic substrate for tryptase remains unknown. There is evidence, however, that 
mouse mast cell tryptase exhibits anticoagulant activity in vivo and in vitro due to its ability 
to degrade fibrinogen (15). Studies with human mast cell tryptase renders fibrinogen 
unclottable by thrombin (16). 
1.1.2.2 Smooth-muscle contraction and peristalsis of the intestine 
Histamine and various Leukotrienes (LTC4 and LTD4) are the classic mediators of MC, 
causing contraction of smooth muscle (SM) via their respective receptors (17). Platelet-
activating factor and PGD2 are also released and can cause contraction (18-20). The effect of 
PGE2 is biphasic; at low concentrations, PGEs relaxes SM, and at higher concentration causes 
contraction via the thronboxane A2 receptor. In addition to the direct contractile effects on the 
muscle, two MC mediators, TNF-α and tryptase, have both been shown to induce 
hyperresponsiveness of SM.  
The mediators of MC degranulation all cause a contractile response or induce 
hyperresponsiveness in SM, with only one mediator, PGE2, capable of causing both 
contraction and relaxation of SM depending on its concentration. Thus, in terms of effects on 
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SM contraction, MC mediators may cause contraction or relaxation, but the evidence suggests 
that the majority of mediators are stimulatory. 
Nematode infections are accompanied by increases in intestinal muscle contractility and 
propulsive activity (21-24) as well as accelerated intestinal transit (25). During such 
infections, the intestinal motor apparatus acts as an extension of the immune system aiding in 
the expulsion of pathogens through increased propulsive activity. Because mice that are MC 
deficient were not able to clear nematode efficiently (26). 
1.1.2.3 Mucosal secretion 
MC signal the presence of the antigen to the enteric nervous system, which uses one of 
the specialized programs from its library of programs to remove the antigens. This is 
accomplished by stimulating mucosal secretion, which flushes the antigen into the lumen and 
maintains it in suspension. The secretory response then becomes linked to powerful 
propulsive motility, which propels the secretions together with the offending agent rapidly in 
the anal direction (27). 
1.1.2.4 Wound healing 
MC are implicate in three phases of wound healing: the inflammatory reaction, 
angiogenesis and extracellular-matrix reabsorption. The inflammatory reaction is mediated by 
released histamine and arachidonic acid metabolites. Compound 48/80 and disodium-
cromoglycate are both able to increase skin breaking strength shortly after wounding. Under 
light and electron microscopy, Trabucchi et al (28) found that small, granule-poor, irregular 
MC mucosal-like mast cells (MLMC) accumulate in the wound. This suggests that the small 
MLMC migrate into the skin during wound healing, and that both connective-tissue mast cells 
(CTMC) and MLMC are involved in tissue repair. Moreover, there is some evidence that MC 
participate in angiogenesis, since heparin is able to stimulate endothelial-cell migration and 
proliferation in vitro, and protamine to inhibit these processes and also angiogenesis in vivo. 
Further studies are needed to demonstrate that protamine is specifically involved in inhibiting 
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heparin-mediated angiogenesis in wounded tissue. Finally, mast cells may play a role in the 
extracellular matrix remodelling, on the basis of in-vitro experiments but there are still no in-
vivo data. 
 
1.1.2.5 Regulation of innate and adaptive immune responses 
MC have an action on dendritic cells (DC) for the migration, maturation and function. 
TNF and IL-1 can facilitate the migration and functional maturation of DC(29, 30), and other 
potential MC products, including IL-16 (31), IL-18 (32), CCL5 (33-36) and prostaglandin E2 
(37) can also promote DC migration. MC derived TNF and exosomes can upregulate 
expression of α6β4 and α6β1 integrins, MHC class II, CD80, CD86 and C, thereby promoting 
functional maturation of DC (38). Histamine can enhance expression of MHC class II and 
costimulatory molecules on DC though both H1 and H2 receptors (39), whereas histamine has 
no effect on LPS-induced DC maturation (40). However, both histamine (41) and 
prostaglandin D2 or prostaglandin E2 (42, 43) can inhibit IL-12 production by DC and induce 
maturation of DC toward an effector DC2 phenotype, leading to the polarization of naïve T 
cells to Th2 cells. 
MC cells can occur in close proximity to T cells at sites of allergic reactions and in other 
immunological responses (44), and MC can promote T cell migration either directly, by 
producing chemotactic factors such as IL-16, XCL1, CCL2, CCL3, CCL4, CCL5, CCL20, 
CXCL10 or LTB4 (45-49), or indirectly, by MC mediated upregulation of expression of cell 
surface adhesion molecules, such as E-selectin, intercellular adhesion molecule 1 and vascular 
cell adhesion molecule 1, on endothelial cells (50-53). 
MC also represent sources of mediators that can contribute to the polarization of T cell 
responses. For example, histamine can promote Th1 cell activation through H1 receptors and 
suppress both Th1 and Th2 cell activation through H2 receptor (54). Moreover, T cells can 
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also influence MC development and/or function (44), suggesting the existence of a complex 
set of cell-cell interactions involving these cell types. 
MC lines and certain tissue MC can express CD154, such MC can interact with B cells 
to induce IgE production in the presence of Il-4 or adenosine but in the absence of T cells (55-
58). Moreover, rat MC protease I can enhance the production of IgG1 and IgE by B cells in 
the presence of IL-4 or LPS (59). Finally, certain MC populations can express mediators that 
can influence B cell development, such as Il-4, IL5, IL-6 and Il-13 (45, 46, 60, 61). Again, the 
in vivo relevance of these observations remains largely to be determined. The potential ability 
of MC to modulate specific antibody responses in vivo has been demonstrated by the injection 
of antigen-pulsed bone marrow-derived cultured MC into naïve mice (62). The antigen-pulsed 
MC induce a much stronger antigen-specific IgG1 response and more IFN-γ production than 
do antigen-pulsed B cells or macrophages. 
1.1.2.6 Peripheral tolerance 
Recent studies have underscored the plasticity of MC in regulating acquired immune 
responses (63-66), the fact that MC may be instrumental in orchestrating TReg-cell-mediated 
peripheral tolerance is unprecedented. It is known that host –derived TGF-β is crucial for the 
peripheral immunosuppression mediated by Treg cells and it is tempting to speculate that TReg-
cell-activated MC responsible for TGF-β production, or the liberation and activation of TGF-
β via other know or unknown factors that MC secrete (67). In addition, TPH1, like 
indoleamine-pyrrole 2,3-dioxygenase, is an enzyme that can metabolize tryptophan and create 
a tryptophan-deficient environment (68). As such, this may be a mechanism used by MC to 
limit T-cell activation.  
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                                                                                       Modified from Galli et al. (63) 
1.1.3 Role of mast cells in pathophysiology 
1.1.3.1 Allergic diseases:  
MC mediate the “early phase” and “late phase reaction” of type I hypersensisitvity 
reactions by releasing mediators after crosslinking of surface-bound IgE by allergen in 
sensitized individuals (69-75). In the late phase reaction, human MC induce the recruitment 
and local activation of eosinophils by expressing factors such as IL-5 after IgE-dependent 
activation, as decribed previously for TH2 cells (76), and induce the recruitment of 
neutrophils by releasing IL-8 and TNF (77, 78).  
In vitro studies indicate that human MC also participate in regulating lymphocyte 
functions in the course of allergic inflammation. After IgE crosslinking, MC produce IL-13, a 
cytokine that supports the production of allergen-specific IgE by B cells. The release of IL-13 
Table 2: products released by activated mast cells
Class of product Products
Preformed Histamine, serotonin (in rodents), heparin and/or 
chondroitin sulphates, tryptase, chymase, major basic              
protein, cathepsin, carboxypeptidase-A
Lipid-derived PGD2, PGE2, LTB4, PAF, LTC4 
Cytokines &
Growth factors GM-CSF, IFN-α, IFN-β, IFN-γ,IL-1α, IL-1β, IL-1R 
antagonist, IL-2, IL-3, IL-5, IL-6, IL-8 (CXCL8), 
IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, 
IL-17 (IL-25), IL-17F, IL-18, IL-22 (IL-TIF), LIF, LTβ, 
M-CSF, MIF, SCF, TGF-β1, TNF, TSLP, bFGF, EGF, 
IGF-1, NGF, PDGF-AA, PDGF-BB, VEGF
Free radicals Nitirc oxide, superoxide
Others Corticotropin-releasing factor, urocortin, substance P
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can be further increased by the presence of IL-4, which is known to shift the cytokine profile 
produced by human MC away from pro-inflammatory cytokines such as TNF, IL-1 and IL-6, 
to Th2 cytokines including IL-13 (77). Human MC can also regulate T-cell functions, for 
example through PGD2, which almost exclusively derives from activated MCand released 
during allergic reactions (79). Recently, exciting new functions of PDG2 have been identified 
that indicate a particular role for PGD2 at the onset and for the perpetuation of asthma in 
young adults. The lipid mediator evokes airway hypersensitivity and chemotaxis of T cells, 
basophils and eosinophils through interaction with two receptors, the prostaglandin D2 
receptor (PTGDR) on granulocytes and smooth muscle cells, and chemoattractant receptor-
homologous molecule expressed on Th2 cells (80, 81).  
 
1.1.3.2 Inflammatory bowel disease (IBD) 
Inflammatory bowel disease (IBD) is a chronic, presumably non-infectious, 
inflammation limited to the large bowel (ulcerative colitis) or anywhere along the 
gastrointestinal tract (Crohn´s disease); the former is a relatively superficial, ulcerative 
inflammation, while the latter is a transmural, granulomatous inflammation. The major 
working hypothesis concerning the pathogenesis of IBD is that the disease is due to abnormal 
and uncontrolled mucosal immune response to one or more normally occurring gut 
constituents (82, 83) 
Since long time MC were known as a key cell type involved in type I hypersensitivity 
(84). Since 20 years, this cell type was involved in a lot of non-allergic diseases in internal 
medicine including chronic obstructive pulmonary disease, Crohn´s disease, ulcerative colitis, 
etc (Table n°1) (85). 
The accumulation of MC at the visible line of demarcation between normal and 
abnormal mucosa suggested that MC played a crucial role in the pathogenesis of the disease, 
either causing further damage or limiting the expansion of damage. Nishida et al (86), found 
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that there were greater numbers of MC than macrophages in the lamina propria of patients 
with inflammatory bowel disease though this was not found in patient with collagenous 
colitis. Interestingly, increased numbers of MC were observed throughout the lamina propria, 
particularly in the upper part of lamina propria, whereas increased numbers of macrophages 
were only seen in the lower part of lamina propria in patients with IBD. This could result 
from that accumulated MC released their proinflammatory mediators, and these mediators, at 
least tryptase (87) and chymase (88), induced macrophage accumulation in the lower part of 
lamina propria. 
Not only the number of MC was elevated (89), but also the contents of MC were greatly 
changed in inflammatory bowel disease in comparison with normal subjects. Laminin, a 
multi-functional non-collagenous glycoprotein, which is normally found in extracellular 
matrix was detected in MC in muscularis propria, indicating that MC may be actively 
involved in the tissue remodeling in Crohn´s diease (90). Similarly, the number of TNF-α 
positive MC was greater in the muscularis propria of patients with Crohn´s disease than that 
in normal controls (91). In the submucosa of involved ileal wall of Crohn´s disease, more 
TNF-α positive MC were found in inflamed area than uninflamed area. Since those TNF-α 
positive MC were the main cell type that expressed TNFα in ileal wall, the successful 
treatment of Crohn´s disease with anti-TNF-α antibody could well be the consequence that the 
antibody neutralized the excessively secreted TNF-α from MC. In chronic ulcerative colitis, 
increased number of substance P positive MC was observed in gut wall, particularly in 
mucosa (92), indicating the possibility of neuronal elements being involved in the 
pathogenesis of the disease. 
Lloyd et al observed that there were marked degranulation of MC and IgE-containing 
cells in the bowel wall of patients with Crohn´s disease (93), and this observation later 
became an important investigation area for understanding the pathogenesis of Crohn´s 
disease. Dvorak et al, described in more detail the degranulation of MC in the ileum of 
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patients with Crohn´s disease (94) with transmission electron microscopy technique. 
Similarly, with electron microscopy technique, degranulation of MC was seen in the intestinal 
biopsies of patients with ulcerative colitis (95). Using immunohistochemistry technique with 
antibodies specific to human tryptase or chymase, both of which are exclusive antigens of 
human MC, MC degranulation was found in the mucosa of bowel walls of patients with 
Crohn´s disease, ulcerative colitis (7) and chronic inflammatory duodenal bowel disorders 
(96). 
MC originated from the resected colon of patients with active CD or UC were able to 
release more histamine than those from normal colon when being stimulated with an antigen, 
colon derived murine epithelial cell associated compounds (97). Similarly, cultured 
colonrectal endoscopic samples from patients with IBD secreted more histamine towards 
substance P alone or substance P with anti-IgE than the samples from normal control subjects 
under the same stimulation (98). In a guinea pig model of intestinal inflammation induced by 
cow´s milk proteins and trinitrobenzenesulfonic acid, both IgE titers and histamine levels 
were higher than normal control animals (99). 
As a proinflammatory mediator, histamine is selectively located in the granules of 
human MC and basophils and released from these cells upon degranulation. A total of four 
histamine receptors H1, H2, H3 and H4 have been discovered (100) and the first three of them 
have been located in human gut (101, 102), proving that there are some specific targets on 
which histamine can work in intestinal tract. Histamine was found to cause a transient 
concentration-dependent increase in short-cicuit current, a measure of total ion transport 
acrossthe epithelial tissue in the gut (103). This could be due to the interaction of histamine 
with H1-receptors that increased Na and Cl ions secretion from epithelium (104). The finding 
that H1-receptor antagonist pyrilamine was able to inhibit anti-IgE induced histamine release 
and ion transport (105) suggests further that histamine is a crucial mediator responsible for 
diarrhea in IBD and food allergy. 
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Tryptase is a tetrameric serine proteinase that constitutes some 20 % of the total protein 
within human MC and is stored almost exclusively in the secretory granules of MC (106) in a 
catalytically active form (107). The ability of tryptase to induce microvascular leakage in the 
skin of guinea pig (108), to accumulate inflammatory cells in the peritoneum of mouse (88) 
and to stimulate release of IL-8 from epithelial cells (109), and the evidence that relatively 
higher secretion of tryptase has been detected in ulcerative colitis (110) implicated that this 
mediator is involved in the pathogenesis of intestinal diseases. However, little is known about 
its actions in IBD but proteinase activated receptor (PAR)-2, a highly expressed receptor in 
human intestine (111) was recognized as a receptor of human MC tryptase (112). PAR-2 
agonists were able to stimulate TNF-α secretion from MC (113) and secreted TNF-α could 
then enhance PAR-2 expression in a positive feedback manner (114).  
Chymase is a serine proteinase exclusively located in the same granules as tryptase and 
could be released from granules together with other preformed mediators. Large quantity of 
active form chymase in MC (115) implicates that this MC unique mediator may play a role in 
MC related diseases. Indeed, chymase has been found to be able to induce microvascular 
leakage in the skin of guinea pig (116), stimulate inflammatory cell accumulation in 
peritoneum of mouse (88), and alter epithelial cell monolayer permeability in vitro (117). 
However, little is know about its actions in IBD but since they are the most abundant granule 
products of MC and have been demonstrated to possess important actions in inflammation, 
they should certainly contribute to the occurrence and development of IBD. 
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1.2 Fibroblasts 
1.2.1 Characteristics of fibroblasts 
Fibroblasts (FB) are embryologically of mesenchymal origin with a spectrum of 
phenotic entities ranging from the non-contractile FB to the contractile myofibroblasts (MFB) 
(Table 3) in a number of intermediate phenotypes having been described (118) including that 
of the prototypical MFB (119, 120). In addition to the features of active fibroblasts and 
prototypical MFB are distinguished by the presence of α-smooth muscle actin containing 
stress fibres, linked in a linear fashion through trans-membrane fibronexus junctions to 
protruding filamentous fibronectin fibres, increased expression of ED-A fibronectin and gap 
junctions (118, 119). MFB are further distinguished from smooth muscle cells by their general 
lack of smooth muscle markers including desmin and smooth musclemyosin. MFB may arise 
from the transdifferentiation of FB and smooth muscle cells. However, whether MFB-like 
cells derived from FB and smooth muscle cells from similar or distinct phenotypic 
populations is debatable and whether FB can differentiate into smooth muscle cells and vice 
versa is uncertain, although recent studies suggest that FB can differentiate into MFB-like 
cells with induction of protein expression patterns previously thought to be characteristic of 
smooth muscle cells (121). 
Table 3 Characteristics of the two types of myofibroblasts found in the bowel wall 
 
 
 
 
 
 
 
Modified from Rieder (122) 
Intestinal cells of Cajal:
-Located in the submucosa and 
muscularis propria in association
with smoothmuscle cells
-Thought to be the pacemaker of 
SMC contraction and bowel
movement
-From a syncytium
Subepithelial myofibroblast : 
-Display VM (vimentin/myosin) 
phenotype
-Located subepithelial directly
beneath the basement membrane
-Form a three-dimensional
network, „Syncytium“
-Display VA (vimentin/αSMA) 
phenotype
-Thought to be important for
epithelial restitution and repair, 
IEC migration
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FB are spindle shaped cells found in the majority of tissues and organs of the body associated 
with extracellular matrix (ECM) molecules. Characteristic features include expression of 
vimentin in the absence of desmin and α-smooth muscle actin. When activated, FB exhibit an 
abundant endoplasmic reticulum and prominent Golgi associated with the synthesis and 
secretion of ECM molecules including collagens, proteoglycans and fibronectin, as well as, as 
families of matrix-modifying proteins such as matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs) These latter molecules are important in tissue 
remodelling and tissue repair (123). 
 
1.2.2 Role of fibroblasts in physiology 
 
1.2.2.1 Maintenance and regulation of extracellular matrix 
One of the major functions of FB is the production and homeostatic maintenance of the 
ECM of the tissue or organ in which they reside. They are metabolically highly active cells, 
being capable of synthesizing and secreting most ECM components, including collagens, 
proteoglycans, fibronectin, tenascin, laminin and fibronectin. FB continually synthesise ECM 
proteins and it has been estimated that each cell can symthesize approximately 3.5 million 
procollagen molecules/cell/day (124). However, the amount they secrete is regulated by 
lysosomal enzymes, such as cathepsins B, D and L, with between 10% and 90 % of all 
procollagen molecules being degraded intracellularly prior to secretion, depending on tissue 
and age. Regulation of this process appears to provide a mechanism for rapid adaptation of 
the amount of collagen secreted following injury (125) (Fig 1). In addition, FB produce 
MMPs and TIMPs, which regulate extracellular degradation of the ECM. FB ECM 
metabolism is regulated by complex mechanisms including cell-cell and cell-matrix 
interactions, as well as a multitude of stimulatory and inhibitory mediators, which may be 
present in their local environment (126). 
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Figure 1: The source and function of fibroblasts in normal states  
                                                                                          Modified from McAnulty (127) 
Fibroblasts exist as several morphological phenotypes ranging from the extremes of the non-
contractile fibroblast to the α-smooth muscle actin stress containing contractile 
myofibroblasttogether with an intermediate phenotype which has been termed the 
protomyofibroblasts. Fibroblasts can transdifferentiate into myofibroblasts and there is some 
evidence to suggest the process may be reversible to at least some extent. Fibroblast 
populations can be maintained or expanded by proliferation of existing populations, or 
derived from epithelial-mesenchymal transition, circulating bone marrow-derived fibrocytes 
or from tissue- derived stem cells. There is also evidence that fibroblasts can undergo 
mesenchymal-epithelial transition and it has recently been shown that genetic programmes 
can be induced in fibroblasts to convert them into pluripotent stem cells. Major functions of 
fibroblasts/myofibroblasts include: synthesis and degradation of the multitude of 
glycoproteins which make up the specialized extracellular matrices of tissues and organs of 
the body which contribute to their specific functions, regulation through cell-matrix 
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interactions of interstitial fluid volume, pressure and appropriate levels of tissue contraction 
for optimum function; playing a critical role in wound healing through cell-cell and cell-
matrix interactions, production and response to mediators, modulation of extracellular matrix 
metabolism, wound contraction and scar resolution. 
 
1.2.2.2 Regulation of fluid volume and pressure 
FB also play an important role in regulating tissue interstitial fluid volume and pressure 
by interaction of β1 integrin receptors which anchor them to ECM proteins, and particularly 
the collagen and laminin binding α2β1 integrin via intracellular forces generated through the 
cytoskeleton (128) (Fig 1). In vitro modeling of these cell-matrix interactions indicate that 
these processes can be modulated by PDGF and endothelin which enhance contraction and 
IL-1 and TNF-α which reduce contraction. 
 
1.2.2.3 Wound healing 
Following tissue injury FB and MFB play a central role in wound healing and repair 
(119). The initial processes following injury include clot formation and plated degranulation, 
releasing mediators to attract inflammatory cells to the wound site which produce additional 
mediators involved in the recruitment of fibroblastic cells derived from several potential 
sources. The fibroblastic cells present in this early phase are highly active synthetically 
replacing the provisional matrix with a more mature ECM including collagens and fibronectin 
under control for mediators produced by inflammatory cells, injured and regenerating 
epithelial cells, and FB themselves. As granulation tissue deposition proceed the fibroblasts 
develop characteristics of myofibroblasts, including the appearance of α-smooth muscle actin 
containing stress fibres (Fig 1). The appearance of these myofibroblasts correlates with 
contraction and closure of the wound through focal adhesions between MFB and the 
extracellular matrix. During the final phases of remodeling and resolution the production of 
MMPs and TIMPs by cells including FB changes from a balance favouring ECM deposition 
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to a matrix degrading environment and MFB are removed by apoptosis. 
 
1.2.2.4 Products released by activated fibroblasts 
FB and MFB are positive for the production of SCF, Granulocyte-macrophage colony-
stimulating factor (GM-CSF), IL-1β, IL-6 and Transforming growth factor beta (TGF-β) 
(129).  
SCF also named mast cell growth factor or kit-ligand, has only recently been cloned and 
has been shown to be encoded on human chromosome 12. It may be of specific importance in 
physiology and pathology since it is produced by several cell types (e.g. fibroblasts, 
keratinocytes, endothelial cells) and since it affects MC growth, survival, secretion and 
adhesion as well as migration into tissues.(130) 
GM-CSF is a naturally occurring substance that is made by the body in response to 
infection or inflammation. It acts on the bone marrow to increase the number of two types of 
white blood cells that fight infection, granulocytes (neutrophils) and monocytes, and makes 
them more effective.(131) 
IL-1 β is a pro-inflammatory cytokine and a potent endogenous inhibitor of gastric acid 
secretion. IL-1β is a soluble protein which are involved in the activation of T-lymphocytes 
and B-lymphocytes.(132) 
IL-6 is a pro-inflammatory cytokine secreted to stimulate immune response to trauma, 
especially burns or other tissue damage leading to inflammation. In terms of host response to 
a foreign pathogen, IL-6 has been shown, in mice, to be required for resistance against the 
bacterium, Streptococcus pneumoniae (133).Furthermore, IL-6 is known to induce survival of 
mouse MC.Indeed, Hu, ZQ et al (134) have shown that IL-6 induced MC development from 
spleen cells of mouse whereas IL-1, IL-5, GM-CSF, TGF-β, and even the MC growth factors, 
IL-9 and SCF, failed to do so. 
TGF-β is a multifunctional peptide that controls proliferation, differentiation, and other 
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functions in many cell types. TGF-β acts synergistically with TGF-α in inducing cellular 
transformation (MIM 190170). It also acts as a negative autocrine growth factor. Specific 
receptors for TGF-β activation trigger apoptosis when activated. Many cells synthesize TGF-β 
and almost all of them have specific receptors for this peptide (135). 
 
1.2.3 Role of fibroblasts in pathophysiology 
 
1.2.3.1 Inferred from fibroblasts in the diseases 
A lot of disease associated with diminished or excess deposition of ECM are likely to be 
related to dysregulation of the injury repair response and fibroblast function. In this context “ 
Injury” is broad ranging including environmental, infectious, cancerous, 
traumatic/mechanical, autoimmune and drug-induced insults. Thus, diseases in which 
fibroblasts, in their various phenotypic guises, play a central role may affect almost all tissues 
and organs of the body (Fig 2). Their importance is further highlighted by the suggestion that 
almost half of all deaths are associated with fibrosing conditions. Diseases associated with 
either increased or decreased ECM deposition, or contraction of tissues result in distorted 
tissue architecture, impaired function and in many cases, particularly where the vital organs 
are involved, significant morbidity and mortality. Dysregulation of several phases of the 
injury repair response, including chronic or repetitive injury, an inappropriate inflammatory 
response, an altered balance of ECM metabolism and deposition, altered phenotypic profiles 
or persistence of myofibroblasts contribute to aberrant tissue repair. 
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Figure 2: Fibroblasts in pathological states 
                                                                                          Modified from McAnulty (127) 
Dysregulated or inappropriate fibroblast function is associated with pathologies which 
diminished or excess extracellular matrix deposition, orinappropiate tissuecontraction is 
feature. Such conditions affect almost all tissues and organs of the body. 
 
1.2.3.2 MMPs and inflammatory bowel disease 
FB and MFB produce the MMPs. MMPs are increasingly recognized to play a 
physiological role in intestinal homeostasis as well as a pathogenetic role in the initiation and 
perpetuation of intestinal inflammatory response (135). Accumulating data demonstrate that 
some of the MMPs (MMP-2, MMP-3, MMP-7) are constitutively expressed and regulate 
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  33 
physiologic processes such as barrier function and mucosal defense, while others (MMP-1, 
MMP-8, MMP-9, MMP-10, MMP-12, MMP-13) are undetectable in normal intestine but 
their dysregulated expression during inflammation may play a role in cell adhesion, immune 
cell migration, and impaired wound healing. Although much work needs to be done on the 
precise role and regulation of MMPs, it is evident that the final outcome of inflammatory 
response depends on a balance between anti-inflammatory MMPs, proinflammatory MMPs 
and TIMPs. 
 
1.2.3.3 Fibrosis and Crohn´s disease 
Inflammation is associated with an infiltrate of immune cells, such as T cells, 
macrophages and neutrophils, and it also often causes severe damage to the tissue in which it 
occurs. In the case of intestinal mucosa, severe inflammation is followed by a loss of 
epithelial cells and a degradation of ECM in the lamina propria, clinically leading to 
ulcerations. Enzymes and mediators mainly secreted by monocytes, intestinal macrophages 
and granulocytes are responsible for this tissue damage. This continous inflammation and 
tissue degradation may consequently lead to fibrosis and stricture formation. 
Oxidants are important contributors to mucosal, and eventually submucosal, tissue 
destruction. Oxygen metabolites, such as oxygen or hydroxide radicals, are produced in large 
amounts by infiltrating leucocytes in the inflamed mucosa (136). The normal intestinal wall 
contains relatively small amounts of antioxidative enzymes (137). 
Besides radical formation, infiltrating and locally activated immune cells respond to 
intestinal inflammation by secreting ECM-modifying and ECM-degrading enzymes (138). 
This permits furtherinfiltration of immune and non-immune cells into the inflamed area, 
finally paving the way for the migration of myofibroblasts. 
If the defect is deeper, with subepithelial tissue damage, the area below the basement 
membrane has to be reconstituted in addition to the epithelial surface. One of the key events 
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in that process is the contraction of the underlying lamina propria to limit the wound area the 
epithelium finally has to cover. A rapid wound closure is important to reduce the time of 
impaired barrier function of the intestinal wall. Recent studies have provided evidence for the 
deleterious consequences of an uncontrolled and longlasting translocation of bacteria from the 
gut lumen into the mucosal wall (139). It is crucial to prevent bacterial translocation, or-if 
impossible-to rapidly detect and sense translocated bacteria, a lesson we have learnt from the 
first susceptibility gene for CD, NOD2/CARD15 (139). In fact, variants of NOD2/CARD15 
causing an increased risk of developing CD are also associated with a higher frequency of 
fibrosing and structuring disease (140-145). Further clinical evidence suggests a genetically 
determinated risk to develop strictures. Some patients obviously have rapidly recurring 
strictures, whereas others permanently have an inflammatory, non-stricturing diease type (Fig. 
3). 
 
 
 
 
 
 
Figure 3: Severity of inflammation and tissue repair  
From Rieder(122) 
Acute intestinal inflammation is normally followed by moderate or limited tissue damage and 
complete restitution. More severe acute or moderate chronic inflammation may result in 
severe or chronic tissue degradation and damage, followed by repair, and may also be 
accompanied by fibrosis and scars. However, severe acute and longlasting chronic tissue 
damage may be associated with severe fibrosis, leading to intestinal strictures and 
obstruction. 
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1.3 Aim of my doctoral thesis 
Garbuzenko et al (146) have shown that the human MC line HMC-1 modulate 
proliferation, collagen synthesis, and collagenase activity of lung fibroblast cell line FHS 738 
(no. HTB-157). MC interact with lung fibroblasts both directly and in a synergistic manner 
with bronchoalveolar (BAL) macrophages and thereby may play an important role in the 
modulation of fibrosis in the lung. Kendall et al (147) have shown that IgE-dependent 
activation of mouse MC can result in the release of mediators that promote fibroblast 
proliferation in the absence of any other cell type and suggest that mast cell-derived TNF-
alpha and TGF-beta 1 contribute substantially to this effect. The role of primary human MC 
on primary human FB and vice versa is largely unknown because of the difficullty to obtain 
the cells from human tissue. The group of Prof. Bischoff found out that FB suppress apoptosis 
in human intestinal MC independently of stem cell factor, IL-3, IL-4 and nerve growth factor. 
But the factor was still unidentified. Effects of human intestinal MC on human intestinal FB 
were also still unknown. 
Thus, the aim of the study was to characterize the interaction of primary human 
intestinal MC and primary human intestinal FB in a co-culture model to elucidate some of the 
underlying molecular mechanisms of the cross-talk between MC and FB. 
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Materials and Methods 
 
2.1 Reagents 
Commercial reagents were obtained from the following sources : HEPES, D-glucose, 
gelatine type B, chymopapain, acetylcysteine, and trypan blue from Sigma Chemical Co (St 
Louis, MO); ampicillin from Bayer AG (Leverkusen, Germany) ; RPMI 1640 medium, 
penicillin, streptomycin, L-glutamine, FCS, gentamycin, and PBS (MgCl2/CaCl2) from 
LifeTechnologies (Grand Island, NY); Turk´s staining solution from Fluka AG (Buchs, 
Switzerland); metronidazol from Fresenius (Bad Homburg, Germany); DNase, BSA (fraction 
IV), pronase, collagenase D, and elastase from Boehringer Mannheim (Mannheim, Germany); 
and Percoll from Pharmacia Biotech (Freiburg, Germany). 
 
2.2 Buffers 
For cell preparation, buffers were used as described previously (149, 150). Cells were 
cultured in RPMI 1640 without phenol red supplemented with10% (v/v) heat-inactivated 
FCS, 25mM HEPES, 2mM L-glutamine, 100 µg/ml gentamicin, 100U/ml penicillin, and 
100µg/ml streptomycin. For cell stimulation, cells were resuspended in HEPES/albumin (HA) 
buffer (containing 20mM HEPES, 0.25 mg/ml BSA, 125mM NaCl, 5mM KCL, and 0.5 mM 
glucose) supplemented with 1mM CaCl2 and 1 mM MgCl2. All buffers were sterilized using 
0.22 µm bottle top filters (Falcon, Heidelberg, Germany). 
 
2.3 Isolation, purification, and culture of human intestinal mast cells  
MC were isolated under sterile conditions in a lamina air flow from surgical tissue 
specimens (macroscopically normal tissue) using a four-step enzymatic dispersion method 
that was previously described (77, 151-154). Briefly, macroscopically normal human 
intestinal tissue was obtained from surgical specimens (border sections, free of tumours cells 
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as determined by histologic examination of the tissue). The tissue was placed in 4°c cold 
buffer immediately after resection until dissection was started. The mucosa was separated 
mechanically from the submucosa/muscular layers. Mucus was removed by incubation with 
acetylcysteine at 1 mg/ml, and epithelial cells were detached by EDTA at 5 mM. The tissue 
was enzymatically digested by a four-step incubation (each for 30min) with four enzymes 
(3mg/ml pronase corresponding to 21 U/ml, 0.75 mg/ml chymopapain corresponding to 0.39 
U/ml, 1.5 mg/ml collagenase D corresponding to 0.405 U/ml, and 0.15 mg/ml elastase 
corresponding to 15.75 U/ml). During the first digestion step, the mucosa was chopped finely 
with scissors. For the third and fourth digestion steps, the incubation buffer was supplemented 
with DNase at 15µg/ml (Corresponding to 15 U/ml). The cells freed after the last two 
digestion steps were separated from tissue fragments by filtration through a polyamide Nybolt 
filter (Pore size, 300µm; Swiss Silk Bolting Cloth Manufacturing Co. Ltd, Zurich, 
Switzerland), washed, pooled, and counted after staining with Turk´s solution. The viability 
of cells was measured by dye exclusion using trypan blue staining. Twenty-nine percent 
(median) of the cells stained positive (range, 20-41%); the positive cells were mostly 
epithelial cells and other cell types, but rarely MC. A differential count of cytocentrifuge 
smears stained with May-Grunwald-Giensa (Sigma) revealed an MC percentage of 4.6 ± 
2.1%. After overnight culture medium (RPMI 1640 supplemented with 10% heat-inactivated 
FCS, 25 mM HEPES, 2 mM glutamine, 100 µg/ml streptomycin, 100 µg/ml gentamycin, 100 
U/ml penicillin, and 0.5 µg/ml amphotericin; all from Invitrogen (Paisley, U.K), MC were 
enriched from non-adherent cells by positive selection of c-kit-expressing cells using 
magnetic cell separation (MACS system; Miltenyi Biotec, Bergisch-Gladbach, Germany) 
coupled with the anti-c-kit mAb YB.B8 (5 ng/ml; BD PharMingen, Hambourg, Germany) (76, 
151-154). Cells were resuspended in 1 ml of HA buffer containing 1 mg/ml albumin and 5 
µg/ml mAb YB5.B8 (directed against human c-kit) and incubated for 30min at 4°c with 
gentle rolling as preiously described (155). The cells were then washed in HA buffer and 
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resuspended in 500 µl of HA buffer containing1 mg/ml albumin. Finally, the cells suspension 
was incubated with a goat anti-mouse IgG Ab coupled to paramagnetic beads (Miltenyi 
Bioted, Bergisch Gladbach, Germany) for 30 min at 4°C. During incubation the tubes were 
gently rolled. After washing in HA buffer, MC were enriched bymagnetic separation of the 
cells using a MACS C1 column placed in a magnetic field (Miltenyi Biotec). The fraction 
containing the c-kit-positive cells (MC purity 50-90%) was cultured (1-2 x 105 MC/ml) in 
presence of recombinant SCF (rSCF; 25 ng/ml; Peprotech, Rocky Hill, NJ). In such 
conditions, MC purity is increased up to 97-100% after 2-4 weeks. Purification of MC can 
also be obtained by long-term culture of non-enriched cell faction (156). This approach has 
the advantage of higher cell numbers and a better culture sufficiency. The disadvantages are 
that the purity is often poor and the required culture period quite long.  
 
 
 
MC after isolation, purification and culture with SCF (staining in May-Grünwald/Giensa) 
 
2.4 Isolation, purification, and culture of human intestinal fibroblasts 
Human intestinal FB were obtained from the adherent cell fraction isolated from 
surgical specimens (Figure 3). Cells were maintained in culture medium for 1-2 weeks until 
they formed a subconfluent layer. For subculturing, cells were detached by trypsin/EDTA 
treatment for 5-20 min (0.05%/0.02%; Biochrom, Berlin, Germany).Then, the cells were 
seeded into fresh dishes at a density of 1 x 105 cells/ml. Such passages were repeated two to 
four times. Depending on the cellular confluence, the culture medium was exchanged every 3-
4 days. To assess FB purity, cells were analysed by immunocytochemistry directed towards 
vimentin, cytokeratin and anti-smooth muscle actin. Vimentin was expressed in all cells 
confirming their mesenchymal origin (157). The epithelial cell marker cytokeratin was 
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generally not expressed, with the exception of two of seven analysed FB cultures displaying, 
respectively 4 and 9.5% positive cells. In three of seven FB preparations, we found 19-42% 
anti-smooth muscle actin-positive cells indicating the presence of myofibroblasts in these 
cultures. FB preparations were negative for CD31 and von Willebrand factor as assessed by 
flow cytometry and thus were not contaminated by endothelial cell (20 and data not shown).  
         
 
 
Confluent FB after isolation, purification and culture (staining in May-Grünwald/Giensa) 
 
2.5 Co-culture of mast cells and fibroblasts 
The principal experimental plan of all experiments is summarized in Fig. 4. For MC/FB 
co-culture or MC culture in the presence of FB-conditioned medium precultured 97-100% 
pure MC were used. Before using MC, cultured cells were washed twice to remove rSCF. For 
co-culture, 1x105 MC were seeded onto confluent FB monolayers in 24-well plates (in Nalge 
Nunc International, Roskide, Denmark) with or without separation of the two cell types using 
Transwell membranes (0.2-µm pore size; Nalge Nunc International). For further evaluation of 
MC/FB interactions, MC were cultured in the presence of FB-conditioned medium (FB 
supernatants). FB supernatants were harvested from confluent FB monolayers cultured for 
24h in 3 ml of culture medium in 25-cm2 culture flasks with or without supplementation of Il-
1β (10ng/ml) or TNF-α (10ng/ml). FB-conditioned medium was stored at-80°C. MC recovery 
rates were expressed as a percent of cell numbers at start of the culture. 
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Figure 4: Experimental setup 
 
2.6 RNA isolation and RT-PCR 
Total RNA was prepared using the RNeasy Mini Kit (Qiagen, Hilden, Germany) (76). 
For RT-PCR, 200 ng of total RNA was treated for 15 min at 37°C with 1U RNase-free DNase 
(Promega, Madison, WI) to remove genomic DNA. After denaturation for 10min at 70°c, 
cDNA was synthesized for 1h at 37°C by adding SuperscriptTM reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA) and 20 pmol oligo dT primers (Pharmacia Uppsala, 
Sweden). 1/10 vol of the cDNA was used for one PCR reaction. Thirty-five cycles (60s at 
94°C, 80s at 60°c, 70s at 72°C) were performed with 2,5U Taq DNA polymerase (Invitrogen) 
and 20pmol of the primers (synthesized by MWG) for quantitative real time PCR assays, 
specific sense and antisense primers for cDNAs were used (158-160). 
 
 
 
 
Non-adherent cells Adherent cells
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2-4 weeks+ rSCF
Collagens 1, 2,3 and 4
TIMP-1 & TIMP- 2
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- TNF-α, IL-1β
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Table 4: Primers sequences 
 
 
 
 
 
 
 
 
 
 
 
 
2.7 Measurement of IL-6 and MMP-1 in supernatants 
IL-6 and MMP-1 were quantified by ELISA according to the manufacturer’s 
instructions. The ELISA kit from R&D Systems (Minneapolis, MN) was used to measure IL-
6, and the ELISA kit from Amersham Pharmacia Biotech (Piscataway, NJ) to measure MMP-
1.  
 
2.8 Stimulation of mast cells and inhibition of fibroblasts 
Mast cells were stimulated in culture medium without addition of SCF by FcεRI cross-
linking using the purified mAb 22E7 (provided by Hoffmann-La Roche, Nutley, NJ) directed 
against a non-IgE binding epitope of the FcεRI α chain. 
 FB were treated with the inhibitors cyclosporin A (Novartis, Basel, Switzerland), 
actinomycin D, apigenin, PD98059, Gö6976, and wortmannin (all from Calbiochem, La Jolla, 
CA) for 1 h prior to stimulation at the concentrations indicated (157). Substances were 
MMP-1 5´-CAGTGGTGATGTTCAGCTAGCTCA-3´          5´-GCCGATGGGCTGGACA-3´
MMP-2 5´-GAGGACTACGACCGCACAA-3´                      5´- CTTCACTTTCCTGGGCAACAA-3´
MMP-3 5´-GTTCCGCCTGTCTCAAGATGA-3´                  5´-TACCCACGGAACCTGTCCC-3´
MMP-7 5´-GGATGGTAGCAGTCTAGGGATTAACT-3´    5´-GGAATGTCCCATACCCAAAGAA-3´
MMP-9 5´-CAAGCTGGACTCGGTCTTTGA -3´                 5´-ACCGACGCGCCTGTGTAC-3´
MMP-12 5´-CGCCTCTCTGCTGATGACATAC-3´                5´-CAGGATTTGGCAAGCGTTG-3´
MMP-14 5´-GAACTTTGACACCGTGGCCAT-3´                  5´-CCGTCCATCACTTGGTTATTCCT-3´
TIMP-1 5´-TGTTGTTGCTGTGGCTGATAGC-3´                  5´-AAGTTCGTGGGGACACCAGA-3´ 
TIMP-2 5´-AGTGGAACGCGTGGCCTAT-3´                         5´-CGGGAGACGAATGAAAGCA-3´
Collagen a1 (I) 5´-TCCGGCTCCTGCTCCTCTTA-3´;           5´-GTATGCAGCTGACTTCAGGGATGT-3´
Collagen a1 (III) 5´-AATGGTGGCTTTCAGTTCAGCT-3´   5´-TGTAATGTTCTGGGAGGCCC-3´
Collagen a1 (IV) 5´-ATGCCCCCTGCCCATT-3´                    5´-ACAGGCCAATCCAAGGTTAGAG-3´
GAPDH 5´-ACCACAGTCCATGCCATCAC-3´                      5´-TCCACCACCCTGTTGCTGTA-3´
Sens Antisens
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dissolved in H2O, ethanol, or dimethyl sulfoxide. Controls were carried out with ethanol and 
dimethyl sulfoxide at a concentration equivalent to the lowest dilution of the inhibitor 
(≤0.1%). 
 
2.9 Analysis of MMP-1 in human gut sections by means of immunohistochemistry 
Serial 4 µm biopsy sections were deparaffinized in xylene, step-rehydrated through 
graded alcohol, and washed with Tris-buffered saline (TBS, 20 mMTrizma base, 150 mM 
NaCl, pH 7,6). Sections were then incubated for 90 min with either MMP-1 antibody (1:1000) 
(abcam ab8480, Cambrige, UK). Sections were washed in TBS, and incubated at room 
temperature for 30 min with an appropriate biotinylated anti-mouse (1:200) (Amersham, Les 
Ulis, France), then for 30 min with an extravidin-alkaline phosphataseconjugate (1:200) 
(Sigma). Finally, sections were incubated in Fast Red TR/Naphtol AS-MX (Sigma), and 
allowed to develop for 20 min at room temperature.Sections were counterstained with 
Mayer´s haematoxylin(Fluka, Saint Quentin Fallavier, France), and mounted in gelatin-
glycerol (1:1) 
 
2.10 Statistics 
All data are expressed as mean ± SEM if not indicated otherwise. Significance was assessed 
by using the Wilcoxon test. A value of p < 0.05 was considered to be statistically significant. 
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Results 
 
3.1 Fibroblast derived IL-6 supports intestinal mast cell survival 
Sellge G et al (1) have shown previously that human intestinal FB suppress apoptosis in 
human intestinal MC independent of SCF, IL-3, IL-4 and NGF(1). We hypothesized that IL-6 
could be considered as the responsible factor because of its ability to trigger mast cell 
development from progenitor cells (134, 161-163). As shown in Fig. 5, intestinal FB are 
capable of producing IL-6 provided that they were stimulated directly by MC in co-culture, 
and less efficiently so by MC mediators such as TNF, IL-1β, tryptase or histamine. 
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Figure 5: MC stimulate FB to express IL-6.  
MC and FB were cultured alone, or co-cultured by seeding MC onto confluent FB layers 
(FB+MC), or FB were incubated with the MC mediators TNF, IL-1β, tryptase, and histamine 
(each 10ng/ml) for 24h. A. IL-6 mRNA expression was analyzed by real time RT-PCR. B. IL-6 
protein produced by FB was measured by ELISA. Data are shown as means ± SEM (n=6, * 
p<0.05 compared to FB alone). 
 
 In order to investigate the role of IL-6 for the survival of intestinal MC, MC were incubated 
with different concentrations of IL-6 (Fig. 6A). Low nanogram amounts of IL-6 supported 
MC survival up to 2 weeks in culture in a concentration dependent manner. In contrast to 
treatment with SCF, all MC incubated with IL-6 died after 3 weeks of culture (Fig. 6A). 
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Interestingly, culture of MC with supernatants from FB stimulated with TNF-α or IL-1β had 
similar effects as IL-6. MC survived for two weeks in culture, but not longer (Fig. 6 B). 
Furthermore, MC survival for two weeks of culture with FB supernatant could be blocked 
using an anti-IL-6 Ab (Fig. 6C). To exclude a possible toxicity of the neutralizing Ab to IL-6, 
MC were incubated in the presence of SCF with or without anti-IL-6 Ab. No differences were 
observed between MC cultured with SCF and MC cultured with SCF and anti-IL-6 Ab (Fig 
6D). Taken together, these findings suggest that MC factors trigger FB to produce IL-6, and, 
vice versa, that IL-6 supports MC survival. 
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Figure 6: FB-derived IL-6 supports intestinal MC survival. 
 MC survival is expressed as percentage of recovery of initial MC numbers at the starting 
  46 
point of the experiments. MC recovery was assessed after 1, 2, and 3 weeks (n=8, * p<0.05 
compared to MC cultures without additions, means ± SEM are shown). A. MC were incubated 
with different concentration of IL-6 (0.2, 2, 10, 20ng/ml) or 25 ng/ml SCF (positive control). 
B. MC were stimulated with 20 ng/ml IL-6, or 25 ng/ml SCF, or supernatants derived from 
FB that have been stimulated with TNF (=SN1) or IL-1β (=SN2) for 24 h. C. MC were 
incubated with 25 ng/ml SCF compared to SN1 and SN2 with or without addition of an 
blocking antibody directed against IL-6. D. Blocking antibody direct against IL-6 were not 
cytotoxic for the MC.  
 
3.2 Human intestinal mast cells induce MMP-1 synthesis in fibroblasts 
To further analyze the cross-talk between intestinal MC and intestinal FB with respect to 
a potential role in the pathogenesis of fibrosis, confluent human intestinal fibroblasts were co-
cultured with MC and analyzed for the expression of collagens and MMPs. Non adherent MC 
were separated from adherent FB by several washing steps before FB mRNA expression was 
quantified by real time PCR. Transcripts for MMP-1, 2, 3, 7, 9, 13 , and 14 (Figure 7A), 
TIMP-1 and 2 (Figure 7B) as well as for collagen a1(I), a1(III) and a1(IV) (Figure 7C) were 
measured (n=6). Only the expression of MMP-1 was significantly increased in response to the 
direct cell-cell contact of FB with MC. 
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Figure 7: Co-culture between MC and FB induce MMP-1 synthesis.  
FB were co-cultured with MC for 24h and mRNA expression was analyzed by real time RT-
PCR. A, MMP family members (n=6, * p<0,05 compared to FB alone). B, TIMP-1 and 2, and 
C, Collagens. 
 
To further evaluate the role of MC in the induction of MMP-1 expression in FB, confluent FB 
were challenged with increasing numbers of MC. As shown in Fig. 8A and B, MMP-1 
expression was clearly dependent on MC numbers. Time course experiments showed a 
substantial induction of MMP-1 mRNA and protein after 24h of co-culture (Fig. 8C and D). 
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Figure 8: Human intestinal MC induce MMP-1 synthesis in FB.  
A, B. FB were co-cultured with different numbers of MC (1 x 104 – 6 x 105 MC/ml) for 24 h 
(n=6, * p<0.05 compared to FB alone, means ± SEM). A. MMP-1 mRNA expression was 
analyzed by real time RT-PCR. B. MMP-1 protein produced by FB was measured by ELISA. 
C, D. FB were co-cultured with 1 x105 MC/ml for 6-72 h (n=6, * p<0.05 compared to FB 
alone, means ± SEM). C. MMP-1 mRNA expression was analyzed by real time RT-PCR. D. 
MMP-1 protein produced by FB was measured by ELISA.  
 
3.3 Role of mast cell mediators in the induction of MMP-1 
FB or MC alone, unstimulated or stimulated by 100 ng/ml mAb 22E7 causing IgE 
receptor (FcεRI) cross-linking, failed to express MMP-1 mRNA or protein. The same result 
was obtained when confluent FB were co-cultured with MC separated by a transwell 
membrane. However, if MC were stimulated by FcεRI crosslinking for one hour, MMP-1 
expression was significantly increased in FB even though they were separated from MC by a 
transwell membrane (n=6, p=0.03) (Fig. 9 A and B). Interestingly, MMP-1 expression in FB 
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could not be further enhanced by MC stimulation if MC and FB were co-cultured in direct 
cell-cell contact (Fig. 10 A and B). In contrast, TIMP-1, the specific inhibitor of MMP-1, was 
not induced in FB by either stimulated or unstimulated MC (data not shown). The next step 
was to determine which MC mediators were responsible for the induction of MMP-1 
expression in FB. FB were treated with several MC mediators for 24h. As shown in Fig. 10 C 
and D, TNF, IL-1β, tryptase and histamine induced a significant increase of MMP-1 
expression in FB. TNF induced MMP-1 expression significantly more strongly compared to 
histamine and tryptase. To demonstrate the effect of MC derived TNF or IL-1β, blocking Abs 
were used to inhibit TNF or IL-1β in FB-MC co-culture experiments. As expected, inhibition 
of TNF or IL-1β resulted in a significant decrease of the induced MMP-1 expression in FB 
(Fig. 9 E and F). 
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Figure 9: Role of MC mediators in the induction of MMP-1. A, B.  
FB were cultured in the absence of MC (FB), or co-cultured with MC by seeding MC onto 
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confluent FB layers (FB+MC), either with or without addition of the antibody 22E7 causing 
MC activation by FcεRI crosslinking. A. MMP-1 mRNA expression was analyzed by real time 
RT-PCR. B. MMP-1 protein was measured by ELISA (n=6, * p<0.05, means ± SEM). C, D. 
FB were incubated with the MC mediators IL-1β, TNF, tryptase, and histamine (each at 10 
ng/ml) for 24h. C. MMP-1 mRNA expression was analyzed by real time RT-PCR. D. MMP-1 
protein produced by FB was measured by ELISA (n=6, * p<0.05, # p<0.05 compared to FB 
alone, means ± SEM). E, F. MC and FB were cultured alone or FB were co-cultured with 
MC, with or without addition of blocking antibodies directed against TNF or IL-1β, 
respectively (n=6,* p<0.05, means ± SEM). 
 
3.4 MMP-1 induction is blocked by the MEK inhibitor PD98059 
FB were treated with several inhibitors prior to co-culture with MC to analyze signalling 
pathways involved in the induction of MMP-1 expression. Following treatment of FB with the 
immunosuppressive drug cyclosporin A, known to prevent activation of the transcription 
factor NF-AT (164), MMP-1 mRNA transcription and protein expression was not reduced. 
The same was found after treatment of FB with Gö 6976, an inhibitor of PKC, or with 
wortmannin, a specific inhibitor of PI3-K (165), suggesting that NF-AT, PKC, or PI3K are 
not involved in MMP-1 induction (data not shown). In contrast, a clear inhibition of MMP-1 
production occurred after a treatment of FB with actinomycin D, apigenin, or PD 98059, 
respectively. Actinomycin D, which inhibits mRNA transcription, was used to distinguish 
between stabilized existing and newly transcribed mRNA (166). Apigenin is an inhibitor of 
mitogen-activated protein kinase (MAPK) signalling cascades (167), and PD98059 is a 
specific inhibitor of the ERK kinase MEK in vitro and in vivo (168). As shown in Fig. 10 A 
and B, actinomycin D completely inhibited up-regulation of MMP-1 mRNA confirming that 
newly transcribed mRNA is responsible for the increase of MMP-1 on the mRNA and protein 
level. Apigenin as well as PD98059 also inhibited the expression of MMP-1 indicating the 
necessity of the MEK-ERK signalling pathway for MMP-1 induction in FB.  
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Figure 10: MMP-1 induction is blocked by the MEK inhibitor PD98059.  
FB were treated with specific inhibitors actinomycin (AC) at 1 µmol/L, apigenin (AP) at 20 
µmol/L, or PD 98059 (PD) at 1 µmol/L before treatment with MC or TNF (10 ng/ml). A. 
MMP-1 mRNA expression was analyzed by real time RT-PCR. B. MMP-1 protein produced 
by FB was measured by ELISA (n=6, * p<0.05 compared to untreated FB, means ± SEM). 
 
3.5 MMP-1 induces loss of confluence in fibroblasts 
MMP-1 has been considered to be a multifunctional modulator since it participates not 
only in turnover of collagen fibrils in the extracellular matrix but also in the cleavage of a 
number of non-matrix substrates and cell surface molecules, suggesting a role in cytokine 
activation and cellular trafficking (169).To test this hypothesis, confluent FB were treated 
with 100 ng/ml MMP-1. As shown in Fig. 11, MMP-1 protein induced a loss of confluence of 
FB after 24 h, and even more pronounced after 72h (Fig. 11 E) compared to controls (Fig. 11 
D, E). Similar observations were made for FB after culture in direct cell-cell contact with MC 
(Fig. 11 C, F).  
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Figure 11: MMP-1 induces loss of confluence in FB.  
FB were incubated alone (A, D), with 100 ng/ml MMP-1 (B, E), or with 1x105 MC/ml (C, F) 
for 24 h (A-C) or 72 h (D-E).Cells stained by May Grünwald/Giemsa were shown. 
 
3.6 Analysis of biopsies derived from human gut 
mRNA for MMP-1 was significantly increased in biopsies derived from patients 
suffering from fibrosis and CD, whereas mRNA for MMP-1 was unchanged in biopsies of 
patients with UC (Fig 12A). To confirm the mRNA data, immunohistochemical analyses were 
performed with an antibody against human MMP-1 (Fig 12 B).  
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Figure 12: MMP-1 expression in the biopsies.  
Biopsies derived from patients with ulcerative colitis, crohn´s Diseas  and fibrosis were 
analyzed by means of immunohistochemistry A, RNA isolated from biopsies were analyzed by 
real time-PCR (n=3, ** p <0,01 compared to control) B, Biopsies were prepared and labeled 
with an antibody against MMP-1. 
 
Control Ulcerative colitis Crohn’s disease Fibrosis 
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Discussion 
 
4.1 IL-6 support human mast cell survival 
In this work it is shown that IL-6 supports human MC survival independent on the 
previously known human MC growth factors SCF, IL-3, and IL-4. Human intestinal MC 
survive up to 3 weeks in co-culture with human intestinal FB, whereas MC mono-cultures die 
within a week (1). We could show that IL-6 is the factor responsible for MC survival 
produced by FB by demonstrating that 1) IL-6 supports MC survival for up to 3 weeks of 
culture as found for FB-dependent MC survival, and 2) MC survival could be reduced or even 
blocked using a neutralizing Ab against IL-6. In line with our results on intestinal MC, IL-6 
has been described before to prolong the survival of cord blood derived MC in a dose-
dependent manner (170). In contrast, the SCF-dependent development of CD34+ cord blood 
derived MC was inhibited by IL-6 (134). In a previous study of the group, it has been reported 
that MC survival in co-culture with FB was clearly enhanced in the presence of IL-1β or TNF 
(1, 78). Since neither IL-1β nor TNF affected MC survival directly, it was likely that both 
cytokines induce or enhance the production of MC survival factor(s) in FB. We could now 
provide an explanation for this phenomenon by showing that IL-1β or TNF induces IL-6 
expression in FB, in line with studies of others on non-intestinal fibroblasts (171-173). 
Fitzgerald et al (174) reported recently that human lung FB express IL-6 in response to 
cellular membranes of the leukemic human mast cell line HMC-1 independent of the 
intercellular adhesion molecule -1 (ICAM-1), IL-1β, and TNF receptor. We found that human 
intestinal FB produce IL-6 in response to co-culture with human intestinal MC which are 
capable of producing a wide range of cytokines including IL-β and TNF (77). Interestingly, 
not only TNF and IL-1β but also specific MC mediators such as tryptase and histamine were 
capable of inducing IL-6 expression in intestinal FB.  
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The regulation of intestinal MC by intestinal FB differs from that of MC regulation by 
endothelial cells. We reported earlier that human umbilical vein endothelial cells (HUVEC) 
support MC growth almost exclusively by membrane-bound factors (SCF/c-kit and adhesion 
molecules VCAM-1/VLA-4) (153). In contrast, FB cause MC survival by releasing soluble 
IL-6, since transwell experiments in which MC were separated from FB yielded similar 
results with regard to MC recovery. Furthermore, FB supernatants also promoted MC growth, 
whereas FB sonicates had only little effect on MC survival (1). Compared to treatment of MC 
with SCF or co-culture of MC with HUVEC, intestinal FB were less effective in promoting 
MC survival (153, 175). This could be due to the lower potency of IL-6 to support MC 
survival compared to SCF. Noteworthy, the amounts of sSCF produced by intestinal FB were 
10-100 times lower than those required for maintaining MC survival in vitro (1). Taken the in 
vitro findings together, MC mediators such as TNF, IL-1β, histamine and tryptase stimulate 
FB to produce IL-6 that, vice versa, supports MC survival; suggesting an close crosstalk 
between these two cell types in intestinal tissues. 
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4.2 Mast cells promote synthesis of MMP-1 by fibroblasts 
MC are thought to play a role in the pathophysiology of fibrosis but the molecular basis 
for their intercellular interaction is basically unknown (146, 176, 177). Garbuzenko et al. 
(175) reported that sonicates of the leukemic MC line (HMC-1) increased human skin 
fibroblast proliferation, collagen synthesis, TIMP-2 and collagen gel contraction. The authors 
concluded, that MC have a direct effect on skin remodeling and fibrosis (175). Both leukemic 
(HMC-1) and dermal MC were found to express fibroblast growth factor 2, fibroblast growth 
factor 7, and heparin-binding epidermal growth factor at least at the mRNA level (178). A 
study in MC-deficient rats and mice aiming to evaluate the role of MC in the development of 
liver fibrosis shown that neither bile duct obstruction nor administration of carbon 
tetrachloride caused an increase in MC density at sites of fibrosis, which occured also in MC 
deficient mice. These data suggest that MC play no role in the development of liver fibrosis in 
rats and mice (179).  
 
In contrast, I found that MC strongly up-regulated the formation of fibrolytic MMP-1 in 
FB whereas profibrogenic TIMP-1 and -2 as well as collagens were not affected by MC. 
MMP-1 is thought to be a key enzyme for interstitial fibrolysis, a process closely that is also 
related to tissue remodeling (178). This enzyme is also known to be a multifunctional 
modulator since it participates not only in the turnover of collagen fibrils in the extracellular 
space but also in the cleavage of a number of non-matrix substrates and cell surface molecules 
(163). We could show that cultured intestinal FB treated with MMP-1 lost their confluence. 
The same was true for FB co-cultured with MC supporting a role of MC-derived mediators in 
the up-regulation of MMP-1 in FB. Tasaki et al. (178), reported that human pancreatic 
periacinar myofibroblasts produce MMP-1 in response to the pro-inflammatory cytokines 
TNF and IL-1β. We could extend these observations for human intestinal FB by showing that 
not only TNF and IL-1β but also the specific MC mediators tryptase and histamine are 
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capable of inducing MMP-1 expression in intestinal FB. Moreover, we found that MC 
dependent MMP-1 expression in FB was mediated via the MEK/ERK branch of the MAPK 
pathway, but occurred independent of PKC or PI3K. These findings are in accordance with 
observations reported for human pancreatic periacinar myofibroblasts showing that inhibition 
of MEK/ERK, but not p38 MAPK and PKC, alters MMP-1 secretion (178) (Fig 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Organisation and function of the MEK-ERK pathway 
                                                                                          Modified fromYeung et al (180) 
Binding of MC mediators induces autophosphorylation (P) on tyrosine residues. These 
phosphotyrosines function as docking sites for signalling molecules including the Grb2-SOS 
complex, which activates the small G-protein Ras by stimulating the exchange of guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP). This exchange elicits a 
conformational change in Ras, enabling it to bind to Raf-1 and recruit it from the cytosol to 
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the cell membrane, where Raf-1 activation takes place. Raf-1 activation is a multi-step 
process that involves the dephosphrylation of inhibitory sites by protein phosphatase 2A 
(PP2A) as well as the phosphorylation of activating sites by PAK (p21rac/cdc42-activated 
kinase), Src-family and yet unknown kinase. Activated Raf-1 phosphorylates and activates 
MEK (MAPK/ERK kinase), which in turn phosphorylates and activates extracellular-signal-
regulated kinase (ERK). The interaction between Raf-1 and MEK can be disrupted by RKIP 
(Raf kinase inhibitor protein; not shown). The whole three-tiered kinase cascade is scaffolded 
by KSR (kinase suppressor of Ras). Activated ERK has many substrates in the cytosol . ERK 
can also enter the nucleus to control gene expression by phosphorylating transcription factors 
such as Elk-1 and other Ets-family proteins.Grb2, growth-factor-receptor-bindingprotein 2; 
SOS, “Son of sevenless”; SRF, serum response factor  
 
In vivo, we observed that mRNA expression of MMP-1 was significantly increased in 
fibrosis and CD but not in UC. This results together with our finding that MC induce MMP-1 
expression in FB, these data correlate with the results of Gelbmann et al (90) that show an 
increase of MC in human biopsies from patients with CD and fibrosis but not in biopsies from 
patients with UC. These data could be helpful in the diagnosis of the disease and a better 
adaptation to the therapies. 
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4.3 Summary 
The data of my doctoral thesis provide new insights into the mechanisms of interactions 
between MC and FB derived from human intestinal mucosa. MC mediators are capable of 
stimulating FB to produce IL-6 that vice versa promotes MC survival. Moreover, MC 
mediators are capable of inducing the expression of MMP-1 in FB, a key enzyme in 
fibrolysis. Taken together the data strongly suggest that MC may play an important role in 
fibrolysis and remodeling of damaged tissue rather than in fibrogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Summary of the work 
MC mediators stimulated FB that produced IL-6 that induce the survival of the MC. Moreover 
stimulated FB produce MMP-1 that induce the lost of confluence of the FB. 
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